X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9067) 9067
Publication (767) 767
Book Review (126) 126
Newsletter (77) 77
Book Chapter (61) 61
Book / eBook (20) 20
Dissertation (12) 12
Magazine Article (7) 7
Conference Proceeding (5) 5
Data Set (4) 4
Paper (4) 4
Reference (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5527) 5527
male (4986) 4986
index medicus (3988) 3988
animals (3720) 3720
female (3153) 3153
hypertrophy (2925) 2925
hypertension (2838) 2838
cardiac & cardiovascular systems (2662) 2662
left-ventricular hypertrophy (2499) 2499
middle aged (2464) 2464
hypertension - drug therapy (2431) 2431
rats (2323) 2323
peripheral vascular disease (1927) 1927
aged (1725) 1725
antihypertensive agents - therapeutic use (1566) 1566
heart (1506) 1506
echocardiography (1491) 1491
heart failure (1482) 1482
hypertension - physiopathology (1444) 1444
adult (1443) 1443
blood pressure - drug effects (1372) 1372
pharmacology & pharmacy (1324) 1324
hypertension - complications (1258) 1258
risk factors (1237) 1237
hypertrophy, left ventricular - drug therapy (1198) 1198
blood pressure (1181) 1181
heart-failure (1171) 1171
cardiac-hypertrophy (1127) 1127
blood-pressure (1084) 1084
left ventricular hypertrophy (1083) 1083
hypertrophy, left ventricular - physiopathology (993) 993
disease models, animal (972) 972
mortality (916) 916
treatment outcome (901) 901
hypertrophy, left ventricular - etiology (872) 872
mice (870) 870
myocardium - pathology (832) 832
fibrosis (803) 803
angiotensin-converting enzyme inhibitors - therapeutic use (791) 791
physiology (776) 776
rats, sprague-dawley (769) 769
research (767) 767
myocardial-infarction (708) 708
cardiomyopathy (699) 699
time factors (692) 692
heart diseases (682) 682
myocardium - metabolism (677) 677
rodents (660) 660
disease (654) 654
oxidative stress (649) 649
expression (628) 628
cardiology (624) 624
urology & nephrology (614) 614
care and treatment (610) 610
drug therapy (609) 609
cardiovascular disease (601) 601
heart failure - drug therapy (598) 598
health aspects (596) 596
medicine (583) 583
ventricular remodeling - drug effects (578) 578
electrocardiography (574) 574
heart enlargement (561) 561
physiological aspects (554) 554
hypertrophy, left ventricular - diagnostic imaging (551) 551
cardiovascular diseases (549) 549
ventricular function, left - drug effects (541) 541
rats, wistar (539) 539
therapy (539) 539
mass (537) 537
prognosis (534) 534
cardiac hypertrophy (526) 526
dysfunction (513) 513
cardiovascular system (512) 512
heart failure - physiopathology (511) 511
prospective studies (496) 496
follow-up studies (486) 486
research article (481) 481
hemodynamics - drug effects (477) 477
hypertrophy, left ventricular - complications (477) 477
apoptosis (471) 471
cardiomegaly - drug therapy (468) 468
ventricle (468) 468
cardiovascular (467) 467
medicine, general & internal (467) 467
medicine, research & experimental (466) 466
angiotensin (459) 459
gene expression (457) 457
article (451) 451
antihypertensive agents - pharmacology (448) 448
heart - drug effects (448) 448
analysis (446) 446
multidisciplinary sciences (442) 442
rats, inbred shr (438) 438
cell biology (436) 436
prevalence (436) 436
myocytes, cardiac - drug effects (418) 418
regression (415) 415
hypertrophy, left ventricular - pathology (405) 405
inhibition (405) 405
angiotensin-ii (403) 403
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9053) 9053
Russian (63) 63
German (36) 36
Spanish (33) 33
French (20) 20
Chinese (8) 8
Italian (3) 3
Polish (3) 3
Hungarian (1) 1
Lithuanian (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 12/2012, Volume 126, Issue 24, pp. 2859 - 2869
Background-The cause and consequences of impaired adrenergic signaling in right ventricular failure/hypertrophy (RVH) are poorly understood. We hypothesized... 
Hypertension | β-adrenergic receptor kinase | Right ventricular hypertrophy | β1-adrenoreceptor | Pulmonary | SU5416 | Dopamine receptors | RECEPTOR KINASE | SYSTEM | ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | dopamine receptors | beta-adrenergic receptor kinase | hypertension, pulmonary | PERIPHERAL VASCULAR DISEASE | right ventricular hypertrophy | beta 1-adrenoreceptor | CONGESTIVE-HEART-FAILURE | Oligonucleotide Array Sequence Analysis | Humans | Myocardial Contraction - physiology | Myocardial Contraction - drug effects | Male | G-Protein-Coupled Receptor Kinase 2 - metabolism | Hypertrophy, Right Ventricular - drug therapy | Receptors, Dopamine D1 - metabolism | Female | Hypertrophy, Right Ventricular - pathology | Hypertension, Pulmonary - drug therapy | Receptors, Adrenergic, beta - metabolism | Hypertrophy, Right Ventricular - metabolism | Xanthenes - pharmacology | Myocytes, Cardiac - cytology | Cells, Cultured | Dopamine - pharmacology | Rats | Hypertension, Pulmonary - metabolism | Cardiotonic Agents - pharmacology | Down-Regulation - drug effects | Rats, Sprague-Dawley | Dobutamine - pharmacology | Down-Regulation - physiology | Animals | Myocytes, Cardiac - drug effects | Receptors, Adrenergic, beta - genetics | Signal Transduction - drug effects | Signal Transduction - physiology | Hypertension, Pulmonary - pathology | Receptors, Dopamine D1 - genetics | Care and treatment | Heart enlargement | Physiological aspects | Dosage and administration | Research | Adrenergic beta blockers | Pulmonary hypertension
Journal Article
Chest, ISSN 0012-3692, 2013, Volume 143, Issue 6, pp. 1699 - 1708
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Molecular Medicine, ISSN 0946-2716, 01/2012, Volume 90, Issue 1, pp. 31 - 43
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 5, p. e0154154
The effects of low concentration of sevoflurane on right ventricular (RV) function and intracellular calcium in the setting of pulmonary arterial hypertension... 
Familial Primary Pulmonary Hypertension - drug therapy | Hypertension, Pulmonary - physiopathology | Male | Hemodynamics - physiology | Familial Primary Pulmonary Hypertension - metabolism | Familial Primary Pulmonary Hypertension - physiopathology | Hypertrophy, Right Ventricular - drug therapy | Hypertrophy, Right Ventricular - physiopathology | Pulmonary Artery - metabolism | Ventricular Dysfunction, Right - physiopathology | Hypertension, Pulmonary - drug therapy | Lung - metabolism | Ventricular Function, Right - drug effects | Ventricular Function, Right - physiology | Hypertrophy, Right Ventricular - metabolism | Ventricular Dysfunction, Right - metabolism | Calcium-Binding Proteins - metabolism | Sarcoplasmic Reticulum Calcium-Transporting ATPases - metabolism | Administration, Inhalation | Rats | Ventricular Dysfunction, Right - drug therapy | Hypertension, Pulmonary - metabolism | Lung - physiopathology | Pulmonary Artery - physiopathology | Pulmonary Artery - drug effects | Rats, Sprague-Dawley | Sevoflurane | Animals | Lung - drug effects | Hemodynamics - drug effects | Methyl Ethers - administration & dosage | Heart | Low concentrations | Calcium | Heart surgery | Ca2+-transporting ATPase | Signal transduction | Rodents | Anesthesia | Blood pressure | Heart failure | Hypertension | Calcium (intracellular) | Pulmonary arteries | Mortality | Contractility | Pulmonary hypertension | Inhalation | Signaling | Hemodynamics | Anesthesiology | Ventricle | Laboratory animals | Respiration | Hypertrophy | Veins & arteries
Journal Article
Journal Article
Journal Article
Biomaterials, ISSN 0142-9612, 2014, Volume 35, Issue 37, pp. 9951 - 9962
Journal Article
Clinical cardiology, ISSN 0160-9289, 2013, Volume 36, Issue 11, pp. 698 - 703
Medical pretreatment before pulmonary endarterectomy (PEA) can optimize right ventricular (RV) function and may improve postoperative outcome in high-risk... 
CATHETERIZATION | CARDIAC & CARDIOVASCULAR SYSTEMS | SILDENAFIL | THERAPY | ARTERIAL-HYPERTENSION | DYSFUNCTION | ENDARTERECTOMY | Single-Blind Method | Hypertension, Pulmonary - diagnosis | Humans | Middle Aged | Hypertension, Pulmonary - physiopathology | Male | Hypertrophy, Right Ventricular - etiology | Endarterectomy | Exercise Tolerance - drug effects | Recovery of Function | Hypertrophy, Right Ventricular - drug therapy | Exercise Test | Hypertrophy, Right Ventricular - physiopathology | Netherlands | Bosentan | Time Factors | Female | Ventricular Dysfunction, Right - physiopathology | Waiting Lists | Hypertension, Pulmonary - drug therapy | Ventricular Function, Right - drug effects | Pulmonary Embolism - complications | Hypertrophy, Right Ventricular - diagnosis | Ventricular Function, Left - drug effects | Treatment Outcome | Ventricular Dysfunction, Right - drug therapy | Antihypertensive Agents - therapeutic use | Ventricular Dysfunction, Right - diagnosis | Magnetic Resonance Imaging | Pulmonary Embolism - diagnosis | Pilot Projects | Sulfonamides - therapeutic use | Ventricular Dysfunction, Right - etiology | Pulmonary Embolism - drug therapy | Aged | Hypertension, Pulmonary - etiology | Ventricular Remodeling - drug effects | Pulmonary Embolism - physiopathology | Endothelin | Cardiac patients | Digital integrated circuits | Pulmonary hypertension
Journal Article
Circulation, ISSN 0009-7322, 06/2012, Volume 125, Issue 23, pp. 2922 - 2932
Background-Pulmonary hypertension (PH) is a multifactorial disease characterized by increased pulmonary vascular resistance and right ventricular failure;... 
eNOS | nitric oxide | xanthine oxidase endothelium | vasodilation | pulmonary hypertension | NO | CARDIAC & CARDIOVASCULAR SYSTEMS | HYPOXIA | BLOOD-PRESSURE | REDUCTASE-ACTIVITY | THERAPY | ARTERIAL-HYPERTENSION | IN-VIVO | PERIPHERAL VASCULAR DISEASE | GENERATION | TISSUES | ISCHEMIA-REPERFUSION | HEMATOLOGY | Xanthine Dehydrogenase - metabolism | Antibiotics, Antineoplastic - toxicity | Nitrates - urine | Xanthine Dehydrogenase - antagonists & inhibitors | Nitrates - pharmacology | Male | Cyclic GMP - blood | Hypertension, Pulmonary - chemically induced | Hypertrophy, Right Ventricular - drug therapy | Hypoxia - metabolism | Pulmonary Circulation - physiology | Ventricular Pressure - physiology | Nitrites - blood | Hypoxia - prevention & control | Hypertension, Pulmonary - drug therapy | Nitric Oxide Synthase Type III - metabolism | Hypertrophy, Right Ventricular - metabolism | Bleomycin - toxicity | Disease Models, Animal | Nitrites - urine | Nitrates - blood | Mice, Inbred C57BL | Enzyme Inhibitors - pharmacology | Ventricular Pressure - drug effects | Hypertension, Pulmonary - metabolism | Nitric Oxide Synthase Type III - genetics | Nitrites - pharmacology | Mice, Knockout | Animals | Allopurinol - pharmacology | Mice | Pulmonary Circulation - drug effects | Animal Feed | Care and treatment | Nitric oxide | Development and progression | Research | Oxidoreductases | Xanthine | Health aspects | Pulmonary hypertension | endothelial nitric oxide synthase
Journal Article